Featured Video
Restabilization of chronic inflammatory demyelinating polyneuropathy patients with IVIG: restabilization phase of the PATH study
12:13 MIN
- CIDP
Learn about the Restabilization Phase of the PATH Trial with IVIG in CIDP patients
Our Experts
Michael Lunn, PhD
National Hospital for Neurology and Neurosurgery, Queen Square, London
Michael Lunn, PhD
National Hospital for Neurology and Neurosurgery, Queen Square, London
- CIDP
Dr Michael Lunn is a Consultant Neurologist, Clinical Lead in Neuroimmunology and Honorary Senior Lecturer at the National Hospital for Neurology and Neurosurgery.
Nabil Moumane, MD
Medical Affairs and Pharmacology, CSL Behring
Nabil Moumane, MD
Medical Affairs and Pharmacology, CSL Behring
- CIDP
- MMN
Nabil Moumane is the Director of Medical Affairs and Pharmacology at CSL Behring.
Jonathan S. Katz, MD
Forbes Norris MDA/ALS Research Center at the California Pacific Medical Center in San Francisco, California
Jonathan S. Katz, MD
Forbes Norris MDA/ALS Research Center at the California Pacific Medical Center in San Francisco, California
- MMN
Jonathan S. Katz, MD, is the Director, Forbes Norris MDA/ALS Research Center at the California Pacific Medical Center in San Francisco, California.
David R. Cornblath, MD
Johns Hopkins University, Baltimore, MD, USA
David R. Cornblath, MD
Johns Hopkins University, Baltimore, MD, USA
- GBS
David R. Cornblath received his MD from Case Western Reserve University and completed his residency and fellowship at the Hospital of the University of Pennsylvania under Prof. A.K. Asbury.
Back to Top